The new law reauthorizes fees charged to drug and device makers, creates new fees for the approval of generic drugs.
The Scientist
Most Recent
The maker of a pregnancy medication takes action against the federal agency for not stopping pharmacies from making and selling cheaper versions of the drug.
ALS patients take their fate into their own hands, self-administering an unapproved chemical and collating their results online.
Dietary supplements can have serious side effects when mixed with prescription drugs, but not all herb-drug interactions are bad.
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Wales creates a database of DNA barcodes for all of its native flowering plants, hoping to guide conservation and drug development efforts.
Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.
Industry experts discuss the agency’s plans to make the drug approval process more transparent.
An Amgen executive refutes accusations that the company published misleading results of its mid-90s clinical trial testing an anemia drug.
The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
